Corbus Pharmaceuticals Inc. has divulged new cannabinoid CB1 receptor antagonists or inverse agonists potentially useful for the treatment of cancer, dyslipidemia, diabetes, obesity, cardiovascular, inflammatory and liver diseases.

Cogent Biosciences Inc. has discovered new tyrosine-protein kinase JAK2 V617F (JH2 domain) inhibitors potentially useful for the treatment of cancer and myeloproliferative diseases.

Perha Pharmaceuticals has discovered new pyrazolo[1,5-a]pyrimidine derivatives acting as adenosine A3 receptor antagonists potentially useful for the treatment of ulcerative colitis, atopic dermatitis, glaucoma, asthma, liver fibrosis, renal disorders, hearing loss and glioblastoma, among others.

Accutar Biotechnology Inc. has synthesized new protein-protein interaction targeted chimera (PPI-TAC) compound comprising an E3 ubiquitin ligase-binding moiety covalently bound to a phosphatidylinositol 3-kinase α (PI3Kα)-targeting moiety. They act as PI3Kα H1047R mutant degradation inducers potentially useful for the treatment of cancer.

Neurocrine Biosciences Inc. has discovered new peptides acting as corticotropin-releasing factor CRF2 receptor agonists potentially useful for the treatment of obesity.

Work at Trained Therapeutix Discovery Inc. has led to the development of new mammalian target of rapamycin (mTOR; FRAP1) inhibitors and high-density lipoprotein (HDL)-derived nanoparticles potentially useful for the treatment of autoimmune diseases, transplant rejection, inflammatory and cardiovascular disorders.

Ensem Therapeutics Inc. has reported new tetracyclic GTPase KRAS (mutant) inhibitors potentially useful for the treatment of cancer.

Jiangsu Hengrui Pharmaceuticals Co. Ltd. has patented new proteolysis targeting chimera (PROTACs) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to cyclin-dependent kinase 7 (CDK7) targeting moiety potentially useful for the treatment of cancer, inflammatory and autoimmune diseases.

Arvinas Inc. has identified new proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase coupled to a mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety acting as HPK1 degradation inducers designed for use in the treatment of cancer.

Haisco Pharmaceutical Group Co. Ltd. has disclosed new lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis.